Diversity in all clinical research—including rare disease research—is currently under scrutiny, partly because of disparities experienced with COVID-19. Rightly so, as data show that 86 percent of genomics studies to date have involved people of European ancestry, which has limited the potential benefits of genomic research for many populations. Rebecca Sutphen, Co-Founder and Chief Medical Officer of InformedDNA, and Board-Certified Genetic Counselor Karmen Trzupek analyze strategies to increase diversity in rare genetic disease trials.

Looking past COVID, the medical world is in turmoil. It’s hard enough for us in manufacturing and marketing to keep up with innovative technologies. Patients and caregivers have it especially tough since they are on the brunt end of disruptive innovations. Every day, patients face a ceaseless onslaught of sort of truths, half-truths, and flat-out lies about their healthcare, and HCPs no sooner graduate from med school than they discover much of their training is obsolete. Flaum Navigators Principal Sander A. Flaum explores how we can engage patients and physicians in the “Next Big Thing.”

Of all the communities touched by the COVID-19 pandemic, healthcare professionals (HCPs) are arguably among those most affected. Specialists on the front lines in primary care, critical care, infectious diseases, and pulmonology roles have experienced COVID-19 first hand—often risking their own health and that of their families to help. A new report from Apollo Intelligence provides a barometer on physicians’ sentiments for 2022, and together with other research, frames a wake-up call to medical device and pharma teams in charge of building a brand presence with prescribers.

Relevate Health solidified the healthcare marketing agency’s position as a market leader in healthcare professional (HCP) omnichannel engagement with the acquisition of Dallas-based ConneXion360. With this acquisition, Relevate Health now provides its omnichannel solutions and agency services to more than 185 brands from 90 pharmaceutical, biotech, and medical device manufacturers, as well as 24 hospital systems.

President Joe Biden on April 5 tasked the U.S. health department with developing a national action plan to tackle the looming health crisis of long COVID, a complex, multi-symptom condition that leaves many of its sufferers unable to work.

Historically, therapies focusing on niche markets face tremendous obstacles, from drug development and clinical trials to drug access. Drew Desjardins – EVP, Chief Strategy Officer, Fishawack Health – analyzes several key challenges for brand marketers readying to launch products in these small markets, along with solutions for driving better stakeholder experiences.  

epocrates, an athenahealth Inc. company that delivers digital clinical decision support to prescribers, shared its commitment to accelerate the company’s fast-growing commercial business and further invest in and innovate its commercial product offerings, following a period of tremendous change in the pharmaceutical industry. To help enhance and broaden epocrates’ services, the company recently brought on Matt Titus – an industry veteran of 13 years – to serve as the organization’s vice president, chief commercial officer.

The American Medical Association (AMA) on January 5 criticized the government’s guidelines on quarantine and isolation in the United States, saying the guidance was “confusing” and risked further spread of COVID-19.

POCN, the largest Nurse Practitioner (NP) and Physician Associate (PA) network in the United States, and HealthSTAR Communications, an integrated omni-channel agency network uniquely positioned to deliver cutting-edge proprietary technology and capabilities to healthcare professionals and patients, partnered to bring POCN’s best-in-class Live Local peer-to-peer educational series focused on NPs and PAs.

Relevate Health announced the appointment of Megan Jones as Chief Operations Officer and Clay Romweber as Chief Revenue Officer.